Immunome, Inc. (NASDAQ:IMNM) Given Average Recommendation of “Moderate Buy” by Analysts

Immunome, Inc. (NASDAQ:IMNM) has earned an average recommendation of “Moderate Buy” from the thirteen ratings firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and twelve have assigned a buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $33.1667.

A number of equities analysts recently issued reports on IMNM shares. Truist Financial upped their price target on shares of Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, May 28th. Barclays started coverage on shares of Immunome in a report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price objective for the company. Wall Street Zen cut Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Wedbush reiterated an “outperform” rating and issued a $31.00 price target on shares of Immunome in a research note on Friday, June 12th. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Immunome in a report on Wednesday, May 13th.

Insider Buying and Selling at Immunome

In related news, Director Isaac Barchas sold 101,050 shares of the firm’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $21.12, for a total value of $2,134,176.00. Following the transaction, the director directly owned 308,504 shares of the company’s stock, valued at approximately $6,515,604.48. This trade represents a 24.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Robert Lechleider sold 55,000 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $19.85, for a total value of $1,091,750.00. Following the completion of the transaction, the insider directly owned 15,805 shares in the company, valued at approximately $313,729.25. This represents a 77.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 316,050 shares of company stock worth $6,578,726 over the last quarter. Company insiders own 7.21% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Creative Planning increased its stake in Immunome by 4.0% in the 3rd quarter. Creative Planning now owns 18,664 shares of the company’s stock worth $219,000 after buying an additional 710 shares in the last quarter. Russell Investments Group Ltd. grew its position in shares of Immunome by 14.4% during the fourth quarter. Russell Investments Group Ltd. now owns 7,417 shares of the company’s stock worth $159,000 after purchasing an additional 935 shares in the last quarter. California State Teachers Retirement System raised its stake in Immunome by 1.8% during the 4th quarter. California State Teachers Retirement System now owns 67,012 shares of the company’s stock valued at $1,439,000 after purchasing an additional 1,167 shares during the period. Assetmark Inc. raised its position in shares of Immunome by 46.6% during the first quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock valued at $99,000 after buying an additional 1,442 shares during the last quarter. Finally, Virtus Investment Advisers LLC raised its position in shares of Immunome by 16.9% during the fourth quarter. Virtus Investment Advisers LLC now owns 13,593 shares of the company’s stock valued at $292,000 after buying an additional 1,970 shares during the last quarter. 44.58% of the stock is currently owned by institutional investors.

Immunome Price Performance

NASDAQ:IMNM opened at $23.61 on Monday. The firm’s 50-day moving average price is $20.96 and its 200-day moving average price is $21.80. The company has a market capitalization of $2.67 billion, a PE ratio of -9.92 and a beta of 2.07. Immunome has a 1-year low of $7.96 and a 1-year high of $27.65.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12. Equities analysts anticipate that Immunome will post -2.06 EPS for the current fiscal year.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.